Skip to main content

Table 1 Demographics and baseline characteristics

From: Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial

  Non-exacerbators Infrequent exacerbators Frequent exacerbators Severe exacerbators
(n = 4685) (n = 1687) (n = 1004) (n = 598)
Male sex, % 76.4 72.1 70.9 82.1
Age, yearsa 62.8 (9.0) 63.0 (9.2) 63.0 (8.8) 64.2 (8.8)
BMI, kg/m2a 26.8 (5.0) 26.4 (5.3) 26.4 (5.2) 25.8 (5.6)
COPD duration, yearsa 7.6 (6.7) 8.2 (6.5) 8.8 (6.7) 9.1 (6.9)
Current smokers, % 48.8 50.3 41.7 44.6
Smoking history, pack-yearsa 38.1 (19.3) 38.2 (19.4) 39.4 (21.3) 40.3 (20.5)
Post-bronchodilator FEV1, La 1.45 (0.46) 1.36 (0.45) 1.32 (0.42) 1.22 (0.42)
Post-bronchodilator FEV1, % predicteda 50.1 (13.3) 48.2 (13.3) 47.2 (12.6) 43.0 (13.0)
GOLD category, %
  2b 51.6 46.2 41.4 26.6
  3/4 48.4 53.8 58.6 73.4
≥ 2 antibiotic courses in prior year, %c 22.6 28.1 38.0 34.8
≥ 2 systemic corticosteroid courses in prior year, %c 9.2 13.5 21.9 23.0
Pulmonary treatment at baseline
Tiotropium, % 27.2 35.4 37.0 36.1
LABAs, total/monotherapy, % 48.1 / 8.5 55.1 / 7.6 61.6 / 7.1 54.8 / 5.4
ICS, total/monotherapy, % 49.5 / 9.9 58.0 / 10.6 64.2 / 9.8 63.7 / 14.2
LABA + ICS, % 39.6 47.5 54.5 49.5
Oral corticosteroids, % 2.0 2.8 3.4 3.5
Xanthines, % 20.2 24.4 26.9 28.4
Oxygen, % 0.6 1.2 0.8 1.5
  1. aValues are means (SD) if not stated otherwise; b23 patients with GOLD category 1 COPD were included; cDue to breathing problems.
  2. The proportions of premature patient withdrawals were 16.9%, 18.3%, 13.0% and 13.2% in the non-, infrequent, frequent and severe exacerbator subgroups, respectively. Median exposure to study medication in all randomised and treated patients was 361 days in severe exacerbators and 363 days in the other groups.
  3. BMI = body mass index; COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in 1 second; GOLD = Global Initiative for Chronic Obstructive Lung Disease; ICS = inhaled corticosteroids; LABA = long-acting β2-agonist; SD = standard deviation.